—A recent study suggests that perimenopausal and postmenopausal women report worse bladder health and function compared to their premenopausal counterparts. Additionally, current hormone use was ...

Avelumab plus BSC significantly improved OS and PFS in advanced urothelial carcinoma patients, irrespective of diabetes status, as shown in the JAVELIN Bladder 100 trial. The trial's findings led to ...

Bavencio shows efficacy and safety in advanced urothelial carcinoma, regardless of diabetes status, as per JAVELIN Bladder 100 trial findings. Diabetes requires careful management in patients ...

Immunocompromised patients with bladder had a higher risk of disease progression and recurrence when compared to their non-immunocompromised counterparts. Immunocompromised patients with bladder ...

WILMINGTON, Del.--(BUSINESS WIRE)--Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab), administered perioperatively in ...

100% (n=7) of evaluable patients (1 CIS, 6 Ta/T1) achieved disease free status. One of these patients was re-treated at 3 months. “I am impressed by these promising NDV-01 data reported at AUA2025.

IMFINZI was generally well tolerated, and no new safety signals were observed in the neoadjuvant and adjuvant settings. Further, adding IMFINZI to neoadjuvant chemotherapy was consistent with the ...

Study showing that Decipher GRID-derived PORTOS signature predicts benefit from dose-escalated radiation therapy also published in Annals of Oncology “The breadth and depth of Decipher-focused data ...